As the Bay Area is Bayer HealthCare’s U.S. headquarters for research, development and biotech manufacturing, it is the ideal spot for the company’s new $100 million product testing facility that that will support the next generation of treatments for patients with hemophilia A.
"Building upon our legacy in hemophilia A, we are delighted to continue Bayer's leadership in working to bring treatment options to patients around the world," said Joerg Heidrich, senior vice president for Product Supply Biotech and Site Head at Bayer Berkeley. "As the Bay Area's third largest biotech employer, we are also proud to be making this contribution to the world's richest center of biotech R&D, investment, and production."
Bayer has a long history in hemophilia, with more than 25 years of research and development on products and approaches to meet varied needs of patients with hemophilia A.
Along with the new facility, this investment is expected to create 325,000 hours of jobs with local union contractors in trades ranging from glaziers to iron workers to sprinkler fitters.
